The market has climbed 1.6% in the last 7 days, contributing to a remarkable 28% increase over the past year, with earnings expected to grow by 17% per annum in the coming years. Though 'penny stock' might sound like a relic of past trading days, it still points to opportunities in smaller or newer companies that can offer significant returns when built on solid financials. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, offering investors a chance to discover hidden value in quality companies.

Here's a peek at a few of the choices from the screener.

CuriosityStream (CURI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CuriosityStream Inc. is a media and entertainment company that offers factual content through various channels, with a market cap of $169.56 million.

Operations: The company's revenue is derived entirely from its Curiosity Stream segment, totaling $71.73 million.

Market Cap: $169.56M

CuriosityStream Inc., with a market cap of US$169.56 million, is trading at 47.8% below its estimated fair value, suggesting potential upside. Despite being unprofitable and having a negative return on equity of -22.14%, the company has a positive free cash flow and sufficient cash runway for over three years. Recent earnings reported sales of US$15.16 million for Q1 2026, but with a net loss of US$1.33 million compared to last year's net income, highlighting ongoing financial challenges despite reduced losses over five years at 32.4% annually. The company's experienced board contrasts with its relatively new management team.

Cytek Biosciences (CTKB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cytek Biosciences, Inc. is a cell analysis solutions company that offers tools for biomedical research and clinical applications, with a market cap of approximately $541.11 million.

Operations: The company's revenue is primarily derived from its Scientific & Technical Instruments segment, which generated $204.17 million.

Market Cap: $541.11M

Cytek Biosciences, Inc., with a market cap of US$541.11 million, reported Q1 2026 revenue of US$44.14 million but remains unprofitable with a net loss of US$18.87 million. Despite this, the company has more cash than debt and sufficient cash runway for over three years based on current free cash flow trends. Its short-term assets significantly exceed liabilities, providing financial stability amid increased debt-to-equity ratios over five years. The board and management are experienced, though profitability is not expected in the near term despite reaffirmed revenue guidance for 2026 between US$205 million to US$212 million.

Applied Energetics (AERG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Applied Energetics, Inc. develops, manufactures, and sells advanced high-performance lasers and optical systems, as well as integrated guided energy systems worldwide, with a market cap of $302.32 million.

Operations: Applied Energetics, Inc. has not reported any specific revenue segments.

Market Cap: $302.32M

Applied Energetics, Inc., with a market cap of US$302.32 million, is pre-revenue with sales under US$1 million and reported a net loss of US$14.87 million for 2025. The company remains debt-free but faces financial challenges, as indicated by its auditor's going concern doubts. Despite securing a follow-on contract worth approximately $250,000 for advanced laser technology research at the University of Rochester, the company's cash runway is less than one year based on current free cash flow trends. Share price volatility remains high over recent months while management lacks extensive experience with an average tenure of 1.6 years.

Turning Ideas Into Actions

• Get an in-depth perspective on all 332 US Penny Stocks by using our screener here.
• Curious About Other Options? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.